Norwegian version of this page

K.G. Jebsen Centre for Cancer Immunotherapy

A Translational Research Program for the Development of New Strategies for Immunotherapy Against Cancer


Our overall focus is to develop novel technologies and immunotherapeutic strategies that overcome immunological tolerance to cancer. In particular, we will focus on leukemia and lymphoma.


  • Induction of neoantigen-reactive T cells from healthy donors June 10, 2019 8:40 PM

    The identification of immunogenic neoantigens and their cognate T cells represents the most crucial and rate-limiting steps in the development of personalized cancer immunotherapies that are based on vaccination or on infusion of T cell receptor (TCR)-engineered T cells. Recent advances in deep-sequencing technologies and in silico prediction algorithms have allowed rapid identification of candidate neoepitopes. However, large-scale validation of putative neoepitopes and the isolation of reactive T cells are challenging because of the limited availablity of patient material and the low frequencies of neoepitope-specific T cells.

News and Events

  • olweus_cimt_text-the-former-president-christoph-huber-and-the-new-president-ozlem-tureci-together-with-newly-elected-member-of-the-executive-board-johanna-olweus Johanna Olweus elected member of the executive board of CIMT June 10, 2019 8:51 PM

    Johanna Olweus, Head of Dept of Cancer Immunology at the Institute for Cancer Research, OUS Radiumhospitalet, and Professor at the University of Oslo, was May 21st elected member of the executive board of CIMT during the CIMT 2019 conference in Mainz, Germany.


The centre was established by a generous donation from Stiftelsen Kristian Gerhard Jebsen.